$Moderna(MRNA.US)
1️⃣ Exploded high after Moderna and Merck announced positive Ph3 result for their personalised mRNA melanoma cancer therapy, the first mRNA cancer treatment to achieve such a milestone. The news triggered a major short squeeze and a sharp re rating of Moderna’s future prospects.
2️⃣ I added a position cause the market narrative changed from a declining COVID company to a potential cancer treatment platform. One successful Ph3 trial can reshape future revenues expectations.
3️⃣ AI stocks depend mainly on earnings, adoption and valuation. MRNA depends on clinical, regulatory and pipeline milestones. In 2 months, I would gauge MRNA by follow through data and institutional support, not hype. 💊🩻🩺
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.